Welcome to Test2Learn!
Pharmacogenomics Certificate Program
Get credentialed using real genetic data in high fidelity learning activities.
Pharmacogenomics Learning Series
(ISCC-PEG)
Explore courses
Pharmacogenomics Certificate Program
Work with faculty experts to apply pharmacogenomics in your practice!The certificate program combines:
- Self-paced, online education
- Live training using highly interactive exercises
Engage with real genomic data in award-winning, competency-based education. Continuing education is available.
ISCC-PEG Pharmacogenomics Learning Series
Self-paced, text-based education to enhance competency of healthcare professionals.
Learn about current and upcoming modules
Pharmacogenomics Nomenclature
This online, self-paced, text-based module explores common nomenclature in pharmacogenomics (PGx).
It was developed by the National Human Genome Research Institute (NHGRI) Inter-Society Coordinating Committee for Practitioner Education in Genomics (ISCC-PEG).
To access, log in to our site (to right of this page; free registration) and click 'continue' to enroll (it's free!).
Planning Committee for the ISCC-PEG Pharmacogenomics Learning Series: Course Director
Spoorthy Reddy
University of Colorado
Additional Content Reviewers
TARGET AUDIENCE
All healthcare professionals
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:- Review the nomenclature for PGx
- Review available evidence sources for pharmacogenomic recommendations.
- Describe how Clinical Pharmacogenetic Implementation Consortium (CPIC) guidelines are developed, the components of a CPIC guideline and how CPIC guidelines can be used by clinicians to make specific prescribing decisions for patient care.
- Retrieve the levels of evidence for gene/drug pairs.
- Integrate information from US Food and Drug Administration (FDA), CPIC, and PharmGKB into pharmacogenomic clinical decision making.
Pharmacogenomics Resources
On-demand
This online, self-paced, text-based module educates healthcare professionals about evidence-based pharmacogenomic resources from the Food & Drug Administration (FDA), the Clinical Pharmacogenetics Implementation Consortium (CPIC), and the Pharmacogenomics Knowledgebase (PharmGKB).
It was developed by the National Human Genome Research Institute (NHGRI) Inter-Society Coordinating Committee for Practitioner Education in Genomics (ISCC-PEG).
To access, log in to our site (to right of this page; free registration) and click 'continue' to enroll (it's free!).
Planning Committee for the ISCC-PEG Pharmacogenomics Learning Series: Course Directors
Philip Empey, PharmD, PhD
Associate Professor and Director, Pharmacogenomics Center of Excellence
University of Pittsburgh School of Pharmacy
Benjamin Brown
American Society of Pharmacovigilance
Additional Content Reviewers
TARGET AUDIENCE
All healthcare professionals
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:- Review available evidence sources for pharmacogenomic recommendations.
- Describe the components of a CPIC guideline and how CPIC guidelines can be used by clinicians to make specific prescribing decisions for patient care.
- Explain how evidence-based guidelines are developed by CPIC.
- Retrieve the levels of evidence for gene/drug pairs.
- Integrate information from FDA, CPIC, and PharmGKB into pharmacogenomic clinical decision making.
Practical Aspects of Pharmacogenomics Implementation
This online, self-paced, text-based module educates healthcare professionals about what elements are involved in implementing a simple population-focused, pharmacogenomic program.
It was developed by the National Human Genome Research Institute (NHGRI) Inter-Society Coordinating Committee for Practitioner Education in Genomics (ISCC-PEG).
To access, log in to our site (to right of this page; free registration) and click 'continue' to enroll (it's free!).
Planning Committee for the ISCC-PEG Pharmacogenomics Learning Series: Course Directors
Otito Frances Iwuchukwu, PhD, MA
Associate Professor
Fairleigh Dickinson University
Jenny Nguyen, PharmD, APh, BCPS
Clinical Pharmacogenomics Specialist
Children's Hospital Los Angeles
Additional Content Reviewers
TARGET AUDIENCE
All healthcare professionals
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:- Describe the components and practical aspects of standard pharmacogenomics implementation.
- Identify the roles of various healthcare professionals in implementation teams.
- Evaluate curated examples of successful implementation programs in different practice settings.
- Apply model principles of pharmacogenomics implementation using a familiar and readily implementable gene-drug or gene-disease pair case example for a clinical practice (or system).
Direct-to-Consumer Pharmacogenomic Testing
This online, self-paced, text-based module educates healthcare professionals towards a better understanding of the benefits and limitations of direct-to-consumer pharmacogenomic testing, when to pursue confirmatory clinical testing, and how to interpret pharmacogenomic test results using evidence-based resources.
It was developed by the National Human Genome Research Institute (NHGRI) Inter-Society Coordinating Committee for Practitioner Education in Genomics (ISCC-PEG).
To access, log in to our site (to right of this page; free registration) and click 'continue' to enroll (it's free!).
Planning Committee for the ISCC-PEG Pharmacogenomics Learning Series: Course Directors
Roseann S. Donnelly (Gammal), PharmD, BCPS
Associate Professor
Massachusetts College of Pharmacy and Health Sciences
Additional Content Reviewers
TARGET AUDIENCE
All healthcare professionals
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:- Differentiate between the delivery models for pharmacogenomic testing.
- Identify the benefits and limitations of direct-to-consumer (DTC) pharmacogenomic testing.
- Interpret DTC pharmacogenomic test results.
- Evaluate the clinical actionability of genetic variants detected by a DTC pharmacogenomic test using evidence-based resources.
- Determine when confirmatory clinical testing is needed when faced with DTC pharmacogenomic test results.
- Explain why confirmatory clinical pharmacogenomic test results may differ from direct-to-consumer pharmacogenomic test results for the same patient.
- Discuss issues related to documenting DTC pharmacogenomic test results in the electronic health record.
The Economics of Pharmacogenomic Testing
This online, self-paced, text-based module educates healthcare professionals towards a better understanding of the benefits and limitations of direct-to-consumer pharmacogenomic testing, when to pursue confirmatory clinical testing, and how to interpret pharmacogenomic test results using evidence-based resources.
It was developed by the National Human Genome Research Institute (NHGRI) Inter-Society Coordinating Committee for Practitioner Education in Genomics (ISCC-PEG).
To access, log in to our site (to right of this page; free registration) and click 'continue' to enroll (it's free!).
Planning Committee for the ISCC-PEG Pharmacogenomics Learning Series: Course Directors
Karen Niemchick, PhD, MHS
Grand Valley State University
Additional Content Reviewers
TARGET AUDIENCE
All healthcare professionals
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:- Understand a basic cost analysis
- Compare benefits of genetic testing with traditional treatment.
- Gain experience in accessing genetic test information.
Navigating Pharmacogenomic Testing Coverage in Medicare Populations
This online, self-paced, text-based module educates healthcare professionals towards a better understanding of the benefits and limitations of direct-to-consumer pharmacogenomic testing, when to pursue confirmatory clinical testing, and how to interpret pharmacogenomic test results using evidence-based resources.
It was developed by the National Human Genome Research Institute (NHGRI) Inter-Society Coordinating Committee for Practitioner Education in Genomics (ISCC-PEG).
To access, log in to our site (to right of this page; free registration) and click 'continue' to enroll (it's free!).
Planning Committee for the ISCC-PEG Pharmacogenomics Learning Series: Course Directors
Sara Rogers, PharmD, BCPS
American Society of Pharmacovigilance
Texas A&M University
Benjamin Brown
American Society of Pharmacovigilance
Christine Formea, PharmD, BCPS, FCCP, FASHP
Children’s Hospital Colorado
Additional Content Reviewers
TARGET AUDIENCE
All healthcare professionals
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:- Define relevant reimbursement related terminology
- Review key components of payer coverage guidance for pharmacogenomics testing
- Describe technical requirements for test reports
- Understand special documentation requirements to show medical necessity